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Background and Objectives. A female patient pre-
sented with splenomegaly and lymphocytosis with
atypical lymphoid cell morphology. We identified
t(2;7)(p12;q21) prompting studies of the translo-
cation breakpoint and its consequences on protein
expression to confirm or otherwise the recently
reported involvement of CDK6 and IG κ genes in the
t(2;7) leading to over-expression of CDK6 protein.
Design and Methods. A variety of clinical and labo-
ratory techniques including cell marker, cytogenetic
and histologic studies were applied in order to estab-
lish the diagnosis. Fluorescence in situ hybridization
(FISH) and Southern blotting were used for mapping
the translocation breakpoint and Western blotting
for assessing protein expression.
Results. Immunophenotyping showed the presence
of a B-cell population with strong expression of
FMC7, CD22, CD79b, CD5 and κ restricted surface
immunoglobulins. Based on morphology and immu-
nophenotypic markers the diagnosis of B-cell non-
Hodgkin’s lymphoma was made. Karyotyping
revealed a clone with t(2;7)(p12;q21-22). Evidence
for clonal evolution with additional abnormalities
including a deletion of the TP53 was present. We
established by FISH and Southern blotting that the
breakpoint on 7q21-22 fell in a region 66kb telom-
eric to the previously reported breakpoint for the
t(2;7) and was the same as that observed in a
t(7;21). CDK6 protein was over-expressed. The
patient received alkylating agents and splenectomy
and is alive but the lymphocytosis persists with evi-
dence of disease progression.
Cyclins, cyclin-dependent kinases (CDK) andcyclin-dependent kinase inhibitors (CKI) reg-ulate the cell cycle and control cell division.
In a variety of cancers, genes encoding these pro-
teins are mutated or deleted resulting in loss of cell
cycle control. Drugs that modulate CDK activities
are being developed.1 A specific chromosome
translocation resulting in the over-expression of
cyclin D1 gene on 11q13 is a common feature of
mantle cell lymphoma (MCL).2 Splenic lymphoma
with villous lymphocytes (SLVL) is an indolent low
grade lymphoma with a gradual accumulation of
neoplastic cells arrested in the G0/G1 phase of the
cell cycle and is the leukemic counterpart of
splenic marginal zone lymphoma (SMZL).3 It is
characterized by splenomegaly and the presence of
circulating villous lymphocytes in the peripheral
blood.4 Two translocations have recently been
described: a t(2;7) (p12;q21-22) in three patients
with SLVL and a t(7;21)(q21-22;q22) in a patient
with SMZL, both involving the CDK6 gene on
Interpretations and Conclusions. We have demon-
strated that CDK6 expression is dysregulated even
when the breakpoint on 7q21-22 is located 66kb
upstream from the coding region. Interestingly, the
precise assignment of the lymphoma type in our case
was not possible even when the splenic histology
was analyzed.
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7q21-22. The breakpoints on the t(2;7) clustered to
a 3.6kb region upstream of the CDK6 gene while
the t(7;21) contained a breakpoint 66kb further
upstream from the t(2;7) cluster on 7q21.5 We
describe a patient with a diagnosis of B-cell lym-
phoma carrying a t(2;7)(p12;q21-22) involving the
κ immunoglobulin light chain gene locus on 2p12
and the CDK6 gene on 7q21-22 with over-expres-
sion of the latter gene.
Case report and laboratory features
A 75-year old female presented in April 1999
with back pain and was found to have lymphocy-
tosis. Physical examination showed splenomegaly
3cm below the costal margin and no lym-
phadenopathy. Computer tomography scanning
confirmed spleen enlargement with intra-abdom-
inal lymphadenopathy. Peripheral blood counts
were as follows: hemoglobin 11.7 g/dL, platelets
287× 109/L and white blood cells (WBC) 46×109/L
with 40×109/L atypical lymphocytes. The majority
of cells in the peripheral blood were of medium
size and a few were large. The chromatin was con-
densed and some cells had an indented or irregu-
lar nucleus. A proportion of cells had mildly baso-
philic cytoplasm without cytoplasmic villi. Immu-
nophenotyping by flow cytometry showed the
presence of a clonal B-cell population with strong
expression of surface immunoglobulin (SmIg) with
κ light chain restriction (88%). The majority of lym-
phocytes were FMC7+ (74%), strongly positive
CD22 (84%), and CD79b (78%+) and co-expressed
CD5 (88%) while they were negative for CD2, CD23
and CD38. According to the chronic lymphocytic
leukemia (CLL) scoring system6 this case was scored
as 1. The presence of the CD5 molecule on the cell
surface, in the absence of a phenotype typical of
chronic lymphocytic leukemia prompted the analy-
sis of cyclin D1 protein expression, but this was not
detected. Examinations of the peripheral blood
morphology and immunonologic markers were
consistent with a diagnosis of B-cell lymphoma.
Because of disease progression with rising WBC
and anemia, the patient was treated with alkylat-
ing agents, first chlorambucil (2 courses) and
thereafter with low dose cyclophosphamide. There
was no response to therapy and further deteriora-
tion of the blood counts and increase in the spleen
size. The patient underwent splenectomy leading to
improvement of the blood counts but the lympho-
cytosis persisted. Current blood counts are hemo-
globin 10.5 g/dL; platelets 149×109/L and WBC
96×109/L. Renal and liver function tests are normal
except for a mildly raised alkaline phosphatase. At
present the patient is alive, 24 months after diag-
nosis, showing evidence of disease progression
with high white blood counts and decreases in
hemoglobin and platelet counts.
Spleen histology showed a nodular and intersti-
tal lymphoid infiltrate effacing the white pulp and
involving the red pulp. The nodules had a biphasic
appearance with the inner zone composed of small
lymphoid cells with round nuclei; while the outer
zone contained cells with slightly more abundant
cytoplasm and scattered large cells with promi-
nent nucleoli. The cytology of the cells in this area
was not typical of marginal zone type since the
nuclei were more irregular than would be expect-
ed in SMZL. Phenotypically the cells expressed
CD20, CD79b, CD5 antigens with κ light chain
restriction. They were negative for CD10, CD23, IgD,
CD3, and cyclin D1. Proliferation was low to mod-
erate. A similar population infiltrated the lymph
node. Although the organization of the infiltrate
was reminiscent of splenic marginal zone B-cell
lymphoma the detailed morphology and immu-
nophenotype (CD5+/IgD) was not typical of this
lymphoma. For these reasons histologically the
diagnosis was that of an unclassified low grade pri-
mary splenic B-cell lymphoma or an atypical form
of SMZL without villous lymphocytes.3
Design and Methods
Karyotype and fluorescent in situ hybridization
(FISH) studies were carried out on peripheral blood
cells cultured with TPA (tetradecanoyl phorbol 12
myristate 13 acetate). G-banding was performed
according to standard procedures. Probes used for
FISH included whole chromosome paints (WCP) for
chromosomes 2 labeled with FITC and chromo-
somes 7, 10 and 13 labeled with biotin (Cambio),
BAC H2NH0029A11 mapping upstream to and con-
taining the first 2 exons of the CDK-6 gene (labeled
with biotin by nick translation) and PAC for κ
immunoglobulin light chain gene (labeled with
digoxigenin by nick translation). Commercial
probes LSI p53 and RB-1 Spectrum Orange (Vysis)
were also applied. FISH was performed according
to standard methods and probes were prepared fol-
lowing the manufacturer's protocols.21 Compara-
tive genomic hybridization (CGH) was performed as
described elsewhere.7
Patient's and control (CEM cell line, normal indi-
vidual and patient’s granulocytes) DNA for South-
ern blotting was extracted according to standard
procedures and digested with the following
enzymes: BamHI, XbaI, SacI, EcoRI, and PvuII (all
from New England Biolabs, USA). DNA blots were
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probed with genomic probes p1305.0 and p1303.0
derived from cosmid 130a6 which spans the clus-
ter of breakpoints 3.6kb from the CDK6 gene
reported in 3 SLVL with t(2;7)(p12;q21) and p67tel
derived from cosmid BMTH9 detecting rearrange-
ments 66-67kb from the cluster and reported in a
SMZL with t(7;21)(q21;q12).5
Cells for evaluating protein expression by West-
ern blotting were lysed at 1×107 cells/mL in HB
buffer (50 mM Hepes pH 7.4, 150 mM NACl, 20
mM EDTA, 10 mM B-glycerophosphate, 0.5% NP40,
1 mM PMSF, 2.5 µg/mL leupeptin and 1% apro-
tinin). Samples were fractionated on 12% SDS-
polyacrylamide gels, blotted on to PVDF mem-
branes and probed with anti-tubulin antibody
(Neomarkers) to confirm equal loading of the lanes.
They were subsequently reprobed with anti-CDK6
antibody (Santa Cruz). Antibody-antigen complex-
es were detected by incubation of the membranes
with HRP-conjugated secondary antibody and
enhanced chemiluminiscence (Amersham).
Results
Karyotype/molecular cytogenetics
G-banded metaphases revealed a clone with a
balanced translocation t(2;7)(p12;q21-22) in all
the cells (Figure 1A). Clonal evolution was evident
in the presence of two subclones. One subclone
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Figure 1. A. Karyotype of a metaphase from subclone 1 with
arrows pointing to the clonal abnormalities: t(2;7)(p12;q21-
22), -17, der(8)t(8;17)(p12;p11) and +12. 
B. WCP for chromosome 2 (green) and 7 (red) depicting the
t(2;7)(p12;q21-22).
Figure 1C. CGH profile showing dim(8p12-pter); dim(17p11-pter) and enh(12). The profile arose from analysis of 10 metaphas-
es. The gain/loss ratios used were 1.20/0.80. The red lines represent the 95% confidence interval of the average ratio (the
blue line).
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contained an unbalanced translocation t(8;17) and
trisomy 12 (Figure 1A). The other displayed complex
rearrangements involving the q arm of the other
chromosome 7 homolog (7q34-35) with 13q and
the q arm of chromosome 10 with the p arm of the
13 resulting in 45, XX, -10, t(2;7)(p12;q21-22),
der(7)t(7;13)(q34-35;q21), der(13)t(13;10)(p11;q?).
Translocation t(8;17) and trisomy 12 were absent
from this latter clone. Chromosome 7 abnormali-
ties were confirmed by experiments using WCP 2,
7, 10 and 13 (Figure 1B).
CGH detected a gain of chromosomal material
from the whole of chromosome 12 as well as a loss
of material from the short arms of chromosomes 8
and 17 (Figure 1C). The gain of 12 profile was
stronger than the loss of 8p and 17p.
Interphase FISH revealed monoallelic TP53 gene
deletion mapping to 17p13 in 52% of the cells.
RB-1 mapping to 13q14 was diploid.
Mapping of the 7q21-22 breakpoint
The breakpoint on t(2;7)(p12;q21-22) was
defined more precisely by FISH and showed co-
localization of signals with a PAC for κ light chain
gene and BAC H2NH0029A11 (Figure 2A). This BAC
spanned the breakpoints on 7q21.2 of all 4 patients
reported by Corcoran et al.5 DNA rearrangement
was only observed by Southern blotting in the PvuII
digests probed with p67tel (Figure 2B) which iden-
tifies a breakpoint ~66-67kb upstream from the
CDK6 gene on 7q21.
Protein expression
Marked overexpression of CDK6 by Western blot-
ting was observed in the patient with t(2;7), while
the 2 control cases of SLVL without chromosome 7
abnormalities showed weak to negative and low
levels of CDK6 expression (Figure 2C).
Discussion
Deregulation of genes contributing to tumorige-
nesis by juxtaposition to Ig gene enhancers is com-
mon in B-lymphoid disorders. These result from
errors in VDJ recombination of the IGH genes.8 Less
frequently, the rearrangements occur during the
processes of class switch recombination or somatic
hypermutation.8 Some translocations, such as
t(11;14)(q13q32) resulting in the over-expression of
cyclin D1, occur in almost all cases of MCL but may
occasionally occur in other lymphoproliferative dis-
orders.9,10 The present investigation is a case study
of a patient with a diagnosis of B-cell lymphoma
that was difficult to classify by standard diagnostic
methods. The diagnosis of CLL was considered but
excluded as although the cells were CD5 positive
and a clone with +12 was identified, neither of these
features is specific for CLL and tumor cells from up
to 20% of patients with SLVL express surface CD5.11
Furthermore, the phenotype and spleen histology of
the reported case were different from those nor-
mally encountered in CLL. The patient’s circulating
peripheral blood lymphocytes were not villous and
spleen histology although not inconsistent was not
typical of SLVL/SMZL. However, the presence of
chromosome 7 abnormalities and more precisely
t(2;7)(p12;q21.2), a translocation described previ-
ously only in cases with SLVL/SMZL5,12 made the
diagnosis of atypical SMZL most likely.
Chromosome 7 abnormalities were confirmed by
experiments with WCP but remained undetected by
CGH. The explanation for this discrepancy is the
fact that the t(2;7)(p12;q21-22) is a balanced
translocation and does not involve any loss or gain
of DNA. Furthermore, the subclone with rearrange-
ments involving chromosomes 7, 13 and 10 con-
stituted a small percentage of cells, below the
threshold of sensitivity for CGH (<50%) (Figures
1A, B). The presence of a subclone containing
t(8;17) with loss of 8p and 17p as well as +12 was
confirmed by CGH (Figure 1C). The stronger inten-
sity of the CGH profile for +12 as compared with
the loss of 8p and 17p may reflect that +12 arose
during clonal evolution before the t(8;17). Howev-
er, karyotypes with +12 but without t(8;17) were
not detected on cytogenetic analysis suggesting
that these cells failed to divide in culture.
CDK4 and CDK 6 in concert with their D type
cyclin partners are responsible for progression
through G1 of the cell cycle while CDK2 with cyclin
E is responsible for progression from G1 to S phase.
These CDKs are serine/threonine kinases which
phosphorylate retinoblastoma protein (pRB) lead-
ing to the release of E2F transcription factor that
controls the S phase genes.13 CDK6 is ubiquitously
expressed in precursors of normal B- and T-cells
and strong expression has been described in acute
lymphoblastic leukemia.14-16 Although the mecha-
nism of dysregulation does not involve DNA
rearrangements of the CDK6 gene, inactivation of
p16, an inhibitor of CDK6, has been observed in
acute T-cell lymphoblastic leukemia.16 Overexpres-
sion of CDK6 is considered to contribute to
leukemia advantage through dysregulation of cell
multiplication and prolonging the life span of the
blasts by favoring progression through the G1
phase in these aggressive leukemias.17
In two of the 3 reported SLVL patients with
t(2;7)5 CDK 6 was dysregulated by juxtaposition to
the κ light chain gene, while in the third, and in a
V. Brito-Babapulle et al.
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case with a t(7;21) with a breakpoint 66kb further
upstream from the breakpoint cluster, CDK6
expression was not tested due to lack of material.5
We observed a marked overexpression of CDK6
despite the fact that the breakpoint of t(2;7) in this
case was 66kb upstream from the reported cluster
and similar to that found in t(7;21).5 Low levels of
CDK6 have been described in a variety of non-
Hodgkin’s lymphoma (NHL)14 and this was seen in
the two cases of SLVL tested which did not have
chromosome 7 abnormalities (Figure 2C). In Cor-
coran’s study, the disease course was not progres-
sive in the 2 patients with t(2:7) as a sole abnor-
mality, suggesting that this translocation on its
own in SLVL is not sufficient to cause aggressive
disease.5 In the present case clonal evolution with
additional abnormalities including the der(7)
t(7;13)(q34-35;q24) was observed. The chromoso-
mal band 7q34-35 harbors the CDK5 and the apop-
tosis regulatory gene.18 Other cytogenetic abnor-
malities in the patient reported here, namely tri-
somy 12, loss of 8p and 17p both of which latter
loci are known to harbor tumor suppressor
genes,19–21 together with clinical features such as
persistent lymphocytosis, anemia and a decrease in
the platelet count maybe be prognostic of future
disease progression. In particular p53 abnormali-
ties, though not common in SLVL are associated
with an aggressive clinical course and poor prog-
nosis21 and the patient described here had con-
tained a mutation in exon 8 (data not shown).
Thus the present study confirms CDK6 deregula-
tion by juxtaposition of the CDK6 gene to the κ
immunoglobulin light chain gene and also demon-
strates over-expression of CDK6 even when the
breakpoint is 66kb away from the reported cluster.
The atypical nature of this B-NHL suggests that
dysregulation of CDK6 by translocation could be a
recurrent abnormality common to primary splenic
B-cell lymphomas including SLVL/SMZL.
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Figure 2. A. Metaphase showing co-localization by FISH of
BAC H2NH0029A11 (green) and PAC for κ gene (red) on
the two derivative chromosomes resulting from t(2;7)
(p12;q21-22) and normal signals on unaffected homologs of
chromosomes 2 and 7. B. Southern blot showing the PvuII
digest of DNA from a normal individual (lane 1), patient’s
granulocytes (lane 2), cell line K1718 (lane 3) and the
patient’s lymphocytes (lane 4) probed with p67tel which
identifies a breakpoint ~66kb upstream from the CDK6
gene. The presence of a band lower than the germline (nor-
mal individual and the patient’s granulocytes) was identified
in the patient’s lymphocytes. C. Western blotting image
showing overexpression of CDK6 in the presented case.
Lanes 1 and 2 were loaded with protein from 2 SLVL patients
without chromosome 7 abnormalities and lane 3 with a sam-
ple from the patient with t(2;7)(p12;q21-22) described here.
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What is already known on this topic
Cyclins regulate the cell cycle and control cell division.
There are reports that show specific translocations
involving cyclin dependent kinase 6 gene.
What this study adds
Here the authors describe another translocation acti-
vating CDK6. In t(2;7)(p12;q21-22) the gene fusion of
κ immunoglobulin light chain and CDK6 results in over-
expression of CDK6.
Potential implications for clinical practice
This translocation is highly likely to be an abnormality
that can be diagnostically and prognostically associat-
ed with primary splenic B-cell lymphoma.
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